Volume 38, Issue 12 p. 2151-2154
VIEWPOINT

Genetic Testing of HTT Modifiers for Huntington's Disease: Considerations for Clinical Guidelines

Jill S. Goldman MS, MPhil

Corresponding Author

Jill S. Goldman MS, MPhil

Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA

Correspondence to: Jill S. Goldman, Department of Neurology, Columbia University Irving Medical Center, 630 W. 168th St., Box 16, New York, NY 10032, USA; E-mail: [email protected]

Search for more papers by this author
Wendy R. Uhlmann MS

Wendy R. Uhlmann MS

Departments of Internal Medicine and Human Genetics, University of Michigan, Ann Arbor, Michigan, USA

Search for more papers by this author
Ali B. Naini PhD

Ali B. Naini PhD

Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA

Search for more papers by this author
Robert L. Klitzman MD

Robert L. Klitzman MD

Department of Psychiatry, Columbia University Irving Medical Center, Mailman School of Public Health, Columbia University, New York, New York, USA

Search for more papers by this author
Karen S. Marder MD, MPH

Karen S. Marder MD, MPH

Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA

Search for more papers by this author
First published: 17 November 2023

Relevant conflicts of interest/financial disclosures: Jill Goldman, Wendy Uhlmann, Ali B. Naini, Robert Klitzman, and Karen Marder have no conflicts of interest or financial disclosures to report.

This Viewpoint is unfunded.

First page image

Data Availability Statement

There is no data being shared.